IRulya Therapeutics Inc (IRLA)

Currency in USD
33.230
+3.230(+10.77%)
Closed·
29.920-3.310(-9.96%)
·
Advertisement
Unusual Pre-Market activity
IRLA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
28.99133.710
52 wk Range
3.660909.980
Key Statistics
Prev. Close
33.23
Open
28.991
Day's Range
28.991-33.71
52 wk Range
3.66-909.98
Volume
8.98K
Average Volume (3m)
30.48K
1-Year Change
-91.3912%
Book Value / Share
-36.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRLA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
75.000
Upside
+125.70%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

IRulya Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 75.000
(+125.70% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Buy72.00+116.67%-New Coverage09/10/2026
Citizens
Buy77.00+131.72%-Maintain29/09/2026
Rodman & Renshaw
Buy70.00+110.65%-New Coverage24/09/2026
Citizens
Buy77.00+131.72%-Upgrade22/09/2026
Craig-Hallum
Buy68.00+104.63%-New Coverage20/08/2026

Earnings

Latest Release
14/08/2026
EPS / Forecast
-12.31 / -9.40
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IRulya (IRLA) Income Statement & Profits

Compare IRLA to Peers and Sector

Metrics to compare
IRLA
Peers
Sector
Relationship
P/E Ratio
−0.4x−1.6x−0.3x
PEG Ratio
0.00−0.010.00
Price/Book
−1.0x1.7x2.6x
Price / LTM Sales
-3.5x2.9x
Upside (Analyst Target)
125.7%304.3%64.3%
Fair Value Upside
Unlock14.2%9.9%Unlock

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
23.52K2.31%705.60K
Other Institutional Investors
527.01K51.82%15.81M
Public Companies & Retail Investors
466.53K45.87%14.00M
Total
1.02M100.00%30.51M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Ikarian Healthcare Master Fund, L.P.9.02%91,7892,754
Ikarian Capital, LLC9.02%91,7892,754

People Also Watch

1.05
ANVS
+2.94%
0.351
KPTI
+11.43%
2.710
NRXP
+4.63%
2.9100
TNON
+3.19%
0.440
HUMA
+24.00%

FAQ

What Is the IRulya (NASDAQ: IRLA) Share Price Today?

The IRulya stock price today is 33.230 USD.

What Stock Exchange Does IRulya (IRLA) Trade On?

IRulya is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for IRulya?

The stock symbol (also called a 'ticker') for IRulya is "IRLA."

What Is the Current IRulya Market Capitalisation?

As of today, IRulya (NASDAQ: IRLA) market cap is 33.800M USD.

What Is IRulya's (IRLA) Earnings Per Share (TTM)?

The IRulya EPS is currently -51.81 (Trailing Twelve Months).

When Is the Next IRulya Earnings Date?

IRulya's next earnings report will be released on 18/11/2026.

Is IRLA a Buy or Sell From a Technical Analyst Perspective?

Based on today's IRulya moving averages and other technical indicators, the daily buy/sell signal for IRLA stock is Strong Buy.

How Many Times Has IRulya Stock Split?

IRulya has split 2 times. (See the IRLA stock split history page for full effective split date and price information.)

How Many Employees Does IRulya Have?

IRulya has 38 employees, based on their latest Companies House report.

What is the current trading status of IRulya (NASDAQ: IRLA)?

As of 16/10/2026, IRulya (IRLA) is trading at a share price of 33.230 USD, with a previous close of 33.230 USD. The stock has fluctuated within a day range of 28.991 USD to 33.710 USD, while its 52-week range spans from 3.660 USD to 909.980 USD.

What Is IRulya (IRLA) Price Target According to Analysts?

The average 12-month price target for IRulya is 75.000 USD, with a high estimate of 98 USD and a low estimate of 65 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +125.70% Upside potential.

What Is the IRLA Premarket Price?

IRLA's last pre-market stock price is 29.920 USD. The pre-market share volume is 138.000, and the stock has decreased by -3.310, or -9.960%.

What Is the IRLA After Hours Price?

IRLA's last after hours stock price is 28.010 USD, the stock has decreased by -5.220, or -15.710%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.